|
【结 构 式】 
|
【分子编号】35179 【品名】(7S,8S,9S,10R,13S,14S,17S)-17-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-7,10,13-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one 【CA登记号】 |
【 分 子 式 】C28H48O2Si 【 分 子 量 】444.77342 【元素组成】C 75.61% H 10.88% O 7.19% Si 6.31% |
合成路线1
该中间体在本合成路线中的序号：(VII)Pregnenolone acetate (I) was reduced with NaBH4 to give alcohol (II), which was subsequently protected as the silyl ether (III) by means of tert-butyl dimethylsilyl chloride and imidazole. Allylic oxidation of (III) with tert-butyl hydroperoxide and chromium hexacarbonyl produced the unsaturated ketone (IV). Addition of methylmagnesium chloride to (IV), with concomitant cleavage of the acetate ester, yielded diol (V), and further Oppenauer oxidation using cyclohexanone and aluminum triisopropoxide generated dienone (VI). Selective reduction of one double bond of (VI) to give enone (VII) was achieved by transfer hydrogenation with cyclohexene and Pd/C. Oxidative cleavage of the A ring of (VII) with NaIO4 and KMnO4 to give (VIII), followed by HF-promoted desilylation furnished the 7beta-methylpregnane seco-acid (IX). This was cyclized with 2,4-dimethoxybenzyl amine (X) affording the azasteroid (XI).
| 【1】 Harris, G.S.; Tolman, R.L.; Ellsworth, K.P.; Rasmusson, G.H.; Chang, B.C.; Patel, G.F.; Bakshi, R.K.; 3-Oxo-4aza-5alpha-7beta-methylpregnan-20-ethers as inhibitors of human type 1 5alpha-reductase: Synthesis and structure-activity relationship. 218th ACS Natl Meet (Aug 22 1999, New Orleans) 1999, Abst MEDI 226. |
| 中间体序号 | 中间体编号 | 品名 | CAS号 | 分子式 | 供应商 | 用于合成 |
|---|---|---|---|---|---|---|
| (I) | 35173 | (3S,8S,9S,10R,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate | 1778-02-5 | C23H34O3 | 详情 | 详情 |
| (II) | 35174 | (3S,8S,9S,10R,13S,14S,17S)-17-[(1R)-1-hydroxyethyl]-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate | 14553-79-8 | C23H36O3 | 详情 | 详情 |
| (III) | 35175 | (3S,8S,9S,10R,13S,14S,17S)-17-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate | C29H50O3Si | 详情 | 详情 | |
| (IV) | 35176 | (3S,8S,9S,10R,13S,14S,17S)-17-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-10,13-dimethyl-7-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate | C29H48O4Si | 详情 | 详情 | |
| (V) | 35177 | (3S,8S,9S,10R,13S,14S,17S)-17-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-7,10,13-trimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthrene-3,7-diol | C28H50O3Si | 详情 | 详情 | |
| (VI) | 35178 | (8S,9S,10R,13S,14S,17S)-17-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-7,10,13-trimethyl-1,2,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one | C28H46O2Si | 详情 | 详情 | |
| (VII) | 35179 | (7S,8S,9S,10R,13S,14S,17S)-17-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-7,10,13-trimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one | C28H48O2Si | 详情 | 详情 | |
| (VIII) | 35180 | 3-[(3S,3aS,5aS,6R,9S,9aS,9bS)-3-((1R)-1-[[tert-butyl(dimethyl)silyl]oxy]ethyl)-3a,6,9-trimethyl-7-oxododecahydro-1H-cyclopenta[a]naphthalen-6-yl]propionic acid | C27H48O4Si | 详情 | 详情 | |
| (IX) | 35181 | 3-[(3S,3aS,5aS,6R,9S,9aS,9bS)-3-[(1R)-1-hydroxyethyl]-3a,6,9-trimethyl-7-oxododecahydro-1H-cyclopenta[a]naphthalen-6-yl]propionic acid | C21H34O4 | 详情 | 详情 | |
| (X) | 32115 | (2,4-dimethoxyphenyl)methanamine; 2,4-dimethoxybenzylamine | 20781-21-9 | C9H13NO2 | 详情 | 详情 |
| (XI) | 35182 | (4aR,4bS,6aS,7S,9aS,9bS,10R)-1-(2,4-dimethoxybenzyl)-7-[(1R)-1-hydroxyethyl]-4a,6a,10-trimethyl-1,3,4,4a,4b,5,6,6a,7,8,9,9a,9b,10-tetradecahydro-2H-indeno[5,4-f]quinolin-2-one | C30H43NO4 | 详情 | 详情 |